Peer-Reviewed Publication
Radiology2026;319(1):e252672.April 1, 2026Journal Article
177Lu-PSMA-617 SPECT/CT for Early Prediction of Overall Survival in Participants with Metastatic Castration-Resistant Prostate Cancer.
Narjess Ayati1,2, Nathan Papa3, Megan Crumbaker1,2,3,4, Shalini Subramaniam5,6, Anthony M Joshua1,2,3, Ramin Alipour7,8, Amir Iravani9,10, Emran Askari11, Sobia Khan1, Surekha Yadav12, Matthias Eiber13, Andrew Weickhardt14,15, Sze-Ting Lee15,16,17, Siobhan Ng18, Roslyn J Francis19,20, Jeffrey C Goh21,22, David A Pattison23,24, Thean Hsiang Tan25, Ian D Kirkwood26,27, Andrew Nguyen1, Michael S Hofman7,8, Shahneen Sandhu7,8, Takanori Hioki1, Julian C J van Oorschodt28, Katrina Devitt1, Kathy Willowson29,30, Shikha Sharma1, Alexandru Stancu31, Stephane Chauvie32, Peter Wilson33, Andrew J Martin5,34, Hayley Thomas5, Martin R Stockler5,35, Ian D Davis36,37, Louise Emmett1,2,3,
1Department of Theranostics and Nuclear Medicine, St Vincent's Hospital Sydney, 390 Victoria St, Darlinghurst, NSW 2010, Australia.
2St Vincent's Clinical School, University of New South Wales, Sydney, Australia.
3Garvan Institute of Medical Research, Sydney, Australia.
4Department of Medical Oncology, Kinghorn Cancer Centre, St Vincent's Hospital, Sydney, Australia.
5NHMRC Clinical Trials Centre, University of Sydney, Sydney, Australia.
6Department of Medical Oncology, Bankstown-Lidcombe Hospital, Sydney, Australia.
7Prostate Cancer Theranostics and Imaging Centre of Excellence, Molecular Imaging and Therapeutic Nuclear Medicine, Peter MacCallum Cancer Centre, Melbourne, Australia.
8Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, Australia.
9Department of Radiology, University of Washington, Seattle, Wash.
10Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, Wash.
11Nuclear Medicine Research Centre, Mashhad University of Medical Sciences, Mashhad, Iran.
12Department of Radiology and Biomedical Imaging, University of California, San Francisco, San Francisco, CA.
13Department of Nuclear Medicine, Rechts der Isar Medical Center, Technical University of Munich, Munich, Germany.
14Olivia Newton-John Cancer and Wellness Centre, Austin Health, Melbourne, Australia.
15School of Cancer Medicine, La Trobe University, Melbourne, Australia.
16Department of Medicine and Department of Surgery, University of Melbourne, Melbourne, Australia.
17Department of Molecular Imaging and Therapy, Austin Health, Melbourne, Australia.
18Department of Oncology, Sir Charles Gairdner Hospital, Perth, Australia.
19Department of Nuclear Medicine, Sir Charles Gairdner Hospital, Perth, Australia.
20Medical School, University of Western Australia, Perth, Australia.
21Department of Medical Oncology, Royal Brisbane and Women's Hospital, Herston, Australia.
22Queensland University of Technology, Brisbane, Australia.
23Department of Nuclear Medicine and Specialised PET Services, Royal Brisbane and Women's Hospital, Herston, Australia.
24School of Medicine, University of Queensland, Brisbane, Australia.
25Department of Medical Oncology, Royal Adelaide Hospital, Adelaide, Australia.
26Nuclear Medicine, PET and Bone Densitometry, Royal Adelaide Hospital, Adelaide, Australia.
27Faculty of Health and Medical Sciences, University of Adelaide, Adelaide, Australia.
28Eindhoven University of Technology, Eindhoven, the Netherlands.
29Royal North Shore Hospital, St. Leonards, Australia.
30Institute of Medical Physics, School of Physics, University of Sydney, Camperdown, Australia.
31Dixit, Torino, Italy.
32Division of Medical Physics, Santa Croce e Carle Hospital, Cuneo, Italy.
33MIM Software, GE HealthCare, Cleveland, Ohio.
34Centre for Clinical Research, University of Queensland, Brisbane, Australia.
35Department of Medical Oncology, Chris O'Brien Lifehouse, Sydney, Australia.
36Monash University Eastern Health Clinical School, Melbourne, Australia.
37Eastern Health, Melbourne, Australia.
Abstract
Background Lutetium 177 (177Lu) prostate-specific membrane antigen (PSMA)-617 SPECT/CT has demonstrated promise as a response biomarker for 177Lu-PSMA-617 therapy. Purpose To predict overall survival (OS) after enzalutamide plus 177Lu-PSMA-617 using quantitative parameters at 177Lu-PSMA-617 SPECT/CT at 6 weeks, as well as prostate-specific antigen (PSA) response, in participants with metastatic ca…
Create a free account to keep reading
Free members get 10 full research views every month across publications, clinical trials, FDA clearances, adverse events, and NIH grants. No credit card required.
Want unlimited research access? See Pro plans